Given the critical importance of FANCI as an ATR target, the phosphorylation state of the FANCI-3SQ cluster may be an appropriate biomarker of the effectiveness of several classes of ATR kinase inhibitor currently in clinical trial for the treatment of cancer (Lecona and Fernandez-Capetillo, 2018). This evidence concerns the gene ATR and cancer.